The mission of the Cell Therapies Core Facility (CTCF) is to produce the highest quality cellular products in support of novel, investigator-initiated clinical trials, and to facilitate the monitoring of immunologic function in cancer patients undergoing immune- and/or gene-based therapies. Cellular products that are administered to patients with therapeutic intent fall under the definition of Pharmaceuticals. The manufacture of these products is regulated by the Food and Drug Administration under the current Good Manufacturing Practices (cGMP) and current Good Tissue Practices (cGTP) statutes. The CTCF was designed, both physically and functionally to work within this regulatory framework, thus relieving the individual investigators of concern for this aspect of their research effort. To further facilitate translational research, the CTCF may be engaged throughout the process of developing clinical trials of novel cell therapy products. Specifically, the CTCF provides pre-clinical scale-up engineering for cell therapy products which have been developed in rodent models, and also handles all aspects of Investigative New Drug (IND) applications, from submission through initial approval. In addition the CTCF provides post-therapy immune monitoring performed on protocol in order to aid in the determination of the efficacy of specific cell and/or gene therapy agents in augmenting anti-neoplasia immunologic function. The CTCF occupies approximately 2700 sf containing five class 10,000 cleanrooms, two conventional labs for handling closed system products, a liquid nitrogen cell banking lab, an apheresis lab, and a cGMP/cGTP compliant materials storage area. All technologists are specifically trained in cGMP/cGTP production methods;all production is done under strictly documented processes;and, all activities, including personnel training, acquisition of materials and equipment, and production are scrupulously documented. A quality management plan under the coordination of a specific, independent individual is in place.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA076292-13
Application #
8214139
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2011-02-01
Budget End
2012-01-31
Support Year
13
Fiscal Year
2011
Total Cost
$83,601
Indirect Cost
Name
H. Lee Moffitt Cancer Center & Research Institute
Department
Type
DUNS #
139301956
City
Tampa
State
FL
Country
United States
Zip Code
33612
Mahajan, Nupam P; Coppola, Domenico; Kim, Jongphil et al. (2018) Blockade of ACK1/TNK2 To Squelch the Survival of Prostate Cancer Stem-like Cells. Sci Rep 8:1954
Gonzalez, Brian D; Hoogland, Aasha I; Kasting, Monica L et al. (2018) Psychosocial impact of BRCA testing in young Black breast cancer survivors. Psychooncology 27:2778-2785
Akuffo, Afua A; Alontaga, Aileen Y; Metcalf, Rainer et al. (2018) Ligand-mediated protein degradation reveals functional conservation among sequence variants of the CUL4-type E3 ligase substrate receptor cereblon. J Biol Chem 293:6187-6200
Chang, James M; Kosiorek, Heidi E; Dueck, Amylou C et al. (2018) Stratifying SLN incidence in intermediate thickness melanoma patients. Am J Surg 215:699-706
Rounbehler, Robert J; Berglund, Anders E; Gerke, Travis et al. (2018) Tristetraprolin Is a Prognostic Biomarker for Poor Outcomes among Patients with Low-Grade Prostate Cancer. Cancer Epidemiol Biomarkers Prev 27:1376-1383
Christy, Shannon M; Schmidt, Alyssa; Wang, Hsiao-Lan et al. (2018) Understanding Cancer Worry Among Patients in a Community Clinic-Based Colorectal Cancer Screening Intervention Study. Nurs Res 67:275-285
Porubsky, Caitlin; Teer, Jamie K; Zhang, Yonghong et al. (2018) Genomic analysis of a case of agminated Spitz nevi and congenital-pattern nevi arising in extensive nevus spilus. J Cutan Pathol 45:180-183
Ji, Xuemei; Bossé, Yohan; Landi, Maria Teresa et al. (2018) Identification of susceptibility pathways for the role of chromosome 15q25.1 in modifying lung cancer risk. Nat Commun 9:3221
Sun, X; Ren, Y; Gunawan, S et al. (2018) Selective inhibition of leukemia-associated SHP2E69K mutant by the allosteric SHP2 inhibitor SHP099. Leukemia 32:1246-1249
Li, Yafang; Xiao, Xiangjun; Han, Younghun et al. (2018) Genome-wide interaction study of smoking behavior and non-small cell lung cancer risk in Caucasian population. Carcinogenesis 39:336-346

Showing the most recent 10 out of 1254 publications